Traditionally, the Netherlands has an excellent reputation for its knowledge economy.
Research and development form a major part of Dutch economic activity, and many companies, such as pharmaceutical companies, profit from the Netherlands as a knowledge science centre with its favourable innovation climate. The Dutch government thinks that pharma research plays a particularly important role in innovation and therefore in the Dutch economy.
It only became clear what is at stake for this knowledge economy when the US-based pharmaceutical company MSD & Co recently announced it would move its subsidiary Organon to the US. Organon’s R&D department is currently based in the Netherlands and employs about 1,100 highly educated and specialised researchers in a specific pharmaceutical field, which would be lost if a transfer is continued.
Since this announcement, the Dutch government is alerted and now plays an important role in its attempt to keep knowledge and skills up and running in the Netherlands.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.